60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand.
Gross profit increased from ($55.9 thousand) to $51.0 thousand.
2024年第一季度淨產品收入同比增長515％，達到105,700美元。
毛利從（55,900美元）增加到51,000美元。
WASHINGTON, May 15, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024.
華盛頓，2024年5月15日（環球新聞專線）——專注於開發傳染病新藥的製藥公司60度製藥公司（納斯達克股票代碼：SXTP；SXTPW）（“公司”）今天公佈了截至2024年3月31日的2024年第一財季財務業績。
Financial Highlights for the Quarter Ended March 31, 2024:
截至2024年3月31日的季度財務摘要：
Net product revenues increased approximately 515% from $17.17 thousand for the first quarter of 2023 to approximately $105.7 thousand for first quarter of 2024; the Company credits growth from domestic commercial sales of ARAKODA.
The Company achieved a gross profit of approximately $51.0 thousand in the first quarter of 2024, compared to an approximate gross loss of $55.9 thousand in the first quarter of 2023. Increased sales volume allowed the Company to overcome fixed cost of goods expense associated with the Drug Supply Chain Security Act that previously led to a gross loss.
Operating expenses were approximately $1.41 million in the first quarter of 2024, compared to approximately $0.899 million in the first quarter of 2023. The increase in operating expenses was primarily due to research and development costs associated with preparatory activities for our babesiosis clinical trial, increased commercial promotional costs, and increased legal, audit and financial expenses.
Net income attributable to common shareholders in the first quarter of 2024 was approximately $0.309 million, or $0.03 per share, compared to a net loss of approximately $2.601 million, or ($1.13) per share in the first quarter of 2023, representing a $2.910 million improvement. This improvement is attributed to a change in the fair value of liabilities and decreased interest expense.
淨產品收入從2023年第一季度的17,170美元增長到2024年第一季度的約105,700美元，增長了約515％；該公司歸因於ARAKODA的國內商業銷售增長。
該公司在2024年第一季度實現了約51,000美元的毛利，而2023年第一季度的總虧損約爲55,900美元。銷售量的增加使公司能夠克服與《藥品供應鏈安全法》相關的固定商品成本支出，該支出先前導致了總虧損。
2024年第一季度的運營支出約爲141萬美元，而2023年第一季度的運營支出約爲89.9萬美元。運營費用的增加主要是由於與我們的巴貝斯蟲病臨床試驗準備活動相關的研發成本、商業促銷成本的增加以及法律、審計和財務支出的增加。
2024年第一季度歸屬於普通股股東的淨收益約爲30.9萬美元，合每股虧損0.03美元，而2023年第一季度的淨虧損約爲260.1萬美元，合每股虧損1.13美元，增長291.0萬美元。這種改善歸因於負債公允價值的變化和利息支出的減少。
Business Highlights for the Quarter Ended March 31, 2024
截至2024年3月31日的季度業務亮點
Following a Type C meeting with the U.S. Food and Drug Administration ("FDA") on January 17, 2024, the Company initiated planning of a clinical study in support of a future indication for tafenoquine for treatment of babesiosis. Enrollment is planned to begin in the summer of 2024.
In February 2024, the Company appointed Kristen Landon as the Company's Chief Commercial Officer to lead commercialization activities related to ARAKODA.
在2024年1月17日與美國食品藥品監督管理局（“FDA”）舉行C型會議後，該公司啓動了一項臨床研究的計劃，以支持他芬諾喹治療巴貝斯蟲病的未來適應症。計劃於2024年夏季開始招生。
2024年2月，公司任命克里斯汀·蘭登爲公司首席商務官，領導與ARAKODA相關的商業化活動。
譯文內容由第三人軟體翻譯。